Case report: Clinical response to a multimodal treatment in a dog with diarrhea and dysbiosisMay 29, 2025This case illustrates that antibiotic use and underlying digestive disorders can lead to dysbiosis and loss of Peptoactetobacter hiranonis, the main bacteria species responsible for the conversion of primary to secondary bile acid. Learn more about the diagnosis, treatment plan, and outcome of this case in this exclusive feature.
Education Center - SponsoredWhy Some Dogs Keep Seizing: Understanding and Managing Refractory Epilepsyby • PRN PharmacalThe severe impact of drug-resistant epilepsy highlights the importance of aiming for complete seizure control in all dogs experiencing seizures. It's crucial to enhance our understanding of the reasons behind drug resistance and how they relate to various causes, progression of the disease, and affected breeds.
Data reveals highest cost drivers for cats and dogsJanuary 22, 2019Vomiting and/or diarrhea and the ingestion of foreign objects are among the top cost drivers of veterinary care for dogs and cats.
Bayer, ParaTheraTech partner to improve treatment of early-life diarrhea in calvesDecember 18, 2018A new licensing agreement will help farmers and veterinarians fight early-life diarrhea in dairy and beef cattle. Bayer Animal Health and ParaTheraTech (PTT) have signed a global agreement to advance new Cryptosporidiosis treatment options for these farm animals.
Probiotics may help dogs with AHDS, according to studyDecember 13, 2018Dogs administered with a high-potency, eight-strain probiotic may recover faster from acute hemorrhagic diarrhea syndrome (AHDS), according to a study.
Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
Zomedica banks on canine diarrhea drugsDecember 19, 2016Zomedica Pharmaceuticals Corp. has started talks with the U.S. Food and Drug Administration on the company’s third proposed veterinary product: an oral suspension formulated for the treatment of canine diarrhea.
